Clinical and Molecular Hepatology

Papers
(The H4-Index of Clinical and Molecular Hepatology is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Preface486
An editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation” by Hong et al.460
Contemporary Trends in Extrahepatic Mortality of Chronic Liver Disease in the United States from 2014 to 2023304
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future231
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”214
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus213
Letter “GLP-1 RA and Reduced Liver and Non-Liver Complications in Adults with T2D and MASLD: A Target Trial Emulation Study”156
Approaches to quantifying hepatitis B virus covalently closed circular DNA140
Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation107
Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis105
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)103
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials103
U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases95
Letter"Novel Genetic Modulators of MASLD Identified Through Genome-Wide Interaction with BMI"95
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific sign78
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer73
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity72
Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?72
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity72
Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease66
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study65
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 c63
Reply to authors’ reply: “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”61
Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease60
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A57
Toward hepatitis C virus elimination using artificial intelligence56
Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”56
HCC Surveillance After Curative Treatment: A New Frontier for Abbreviated MRI Editorial on: “Non-contrast MRI for Detection of Late Recurrent Hepatocellular Carcinoma After Curative Treatment: Compari55
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease55
Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis54
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial52
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma50
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma49
Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target49
2025 KASL clinical practice guidelines for management of hepatitis C47
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment47
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–202347
Liver organoids: Current advances and future applications for hepatology46
Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment45
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma45
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevate45
What is new in the 2024 Chinese guidelines for fatty liver disease?43
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review43
Correspondence to the letter titled “Revisiting the Role of Non-Contrast MRI in Recurrent HCC: Bridging Diagnostic Performance and Real-World Applicability”43
0.34649896621704